These are JPMorgan's top drug picks heading into earnings.
JPMorgan is eyeing a few drug manufacturers ahead of their earnings reports as investors continue to sell out of major technology firms. Major market trends in the first half of 2024 have shifted and sparked a rotation out of large technology stocks into less-loved areas of the market, including value stocks and small caps. The S & P 500 dropped about 0.8% last week, while the Dow Jones Industrial Average — whose constituents include Johnson & Johnson and Merck — added nearly 0.8%.
The analyst notes that any potential upside in the quarter from Mounjaro and Zepbound — Lilly's tirzepatide medications that treat Type 2 diabetes and manage weight, respectively — could be offset from supply chain headwinds tied to diabetes treatment Trulicity. LLY YTD mountain Eli Lilly stock. Over the long term, however, Schott forecasts sales of Mounjaro and Zepbound growing from $16.5 billion in 2024 to $27 billion and $36.5 billion in 2025 and 2026, respectively.
Regeneron Pharmaceuticals Inc Eli Lilly And Co Markets Investment Strategy Johnson & Johnson Merck & Co Inc Dow Jones Industrial Average S&P 500 Index Business News
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Here are JPMorgan’s top stock picks heading into JulyJPMorgan's newest additions to its list of top stock picks include AT&T and First Citizens BancShares.
Read more »
JPMorgan stock price at record high ahead of Q2 earningsJPMorgan earnings kick off earnings season on 12 July, but a slowdown is expected despite the stock’s run to record highs.
Read more »
JPMorgan says the drop in this beer stock is overdone and calls it a buying opportunityThis premier beer stock could be poised for gains after a sell-off.
Read more »
JPMorgan sees near 20% upside left in Apple stock, adds it to focus listJPMorgan sees near 20% upside left in Apple stock, adds it to focus list
Read more »
Any Near-Term Rebound in Crypto Market Likely to be Temporary: JPMorganWill Canny is CoinDesk's finance reporter.
Read more »
Jamie Dimon’s JPMorgan warns Bitcoin price is ‘too high at present’Jamie Dimon’s JPMorgan warns Bitcoin price is ‘too high at present’
Read more »